Pharmaceutical Product Monograph: Cyclophosphamide (500 mg, 1 g)
In the pharmaceutical industry, Cyclophosphamide is a nitrogen mustard derivative and a potent Alkylating Agent. As a pharmacist and manufacturer, I view this molecule as a “Biochemical Pro-drug”—it is technically inert until it is metabolized by the liver, at which point it becomes one of the most versatile tools in both Oncology and Rheumatology.
At your WHO-GMP facility in Mumbai, Cyclophosphamide is a critical SKU for treating high-proliferation malignancies and severe autoimmune crises.
Therapeutic Profile: Primary Indications
Cyclophosphamide’s “main use” is bifurcated between its role as a cytotoxic chemotherapy and its role as a high-potency immunosuppressant.
| Indication | Clinical Context | Technical Rationale |
| Malignant Lymphomas | Hodgkin’s & Non-Hodgkin’s | A core component of the CHOP regimen (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone). |
| Breast Cancer | Adjuvant Therapy | Often combined with Doxorubicin (the AC regimen) to prevent recurrence after surgery. |
| Leukemia | ALL / CLL | Used to induce remission and as a conditioning agent before bone marrow transplants. |
| Nephrotic Syndrome | Pediatric Nephrology | Used in children when steroid treatments fail to control kidney inflammation. |
| Severe Lupus (SLE) | Rheumatology | The “Gold Standard” for treating Lupus Nephritis (kidney involvement) to prevent organ failure. |
Mechanism: DNA Cross-Linking
Cyclophosphamide sabotages the “instruction manual” of the cell to prevent replication:
Hepatic Activation: It is a pro-drug. It must be technically activated by Cytochrome P450 enzymes in the liver into Aldophosphamide.
Phosphoramide Mustard: This active metabolite enters cells and attaches an alkyl group to the Guanine base of DNA.
Cross-Linking: It creates “bridges” (cross-links) between DNA strands. These bridges prevent the DNA from unzipping, making it impossible for the cell to divide.
Apoptosis: The cell detects the structural failure and triggers Programmed Cell Death.
The Pharmacist’s “Technical Warning”
Hemorrhagic Cystitis: As a pharmacist, I must emphasize the risk of bladder bleeding. The metabolite Acrolein is toxic to the bladder lining. Patients must be “hydrated aggressively” and often given Mesna (a technical uro-protective agent) to neutralize Acrolein.
Infertility Risk: Cyclophosphamide can cause permanent sterility in both men and women. Counsel patients on sperm or egg banking before starting a high-dose cycle.
The “Nadir” Period: Suppression of white blood cells usually peaks between 7 to 14 days post-dose. This is the period of highest infection risk.
Teratogenicity: It is highly damaging to a developing fetus. Strict contraception is technically mandatory during and for 6 months after treatment.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilized vs. Dry Fill” USP: On your digital marketplace, highlight if your product is Lyophilized. A freeze-dried cake reconstitutes faster and more clearly than dry-filled powder, which is a significant technical advantage for oncology nurses.
Storage Stability: Cyclophosphamide is sensitive to heat (it can liquefy if stored above 30°C). For Zone IVb (tropical) exports, climate-controlled shipping is a technical necessity to prevent the “melting” of the API.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Cyclophosphamide 500 mg and 1 g vials to support your registration in international B2B oncology and rheumatology tenders.